Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $15.71

Inozyme Pharma, Inc. (NASDAQ:INZY) has been given a consensus rating of “Buy” by the seven analysts that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year is $15.71.

Several research analysts recently commented on INZY shares. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Stifel Nicolaus started coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $12.00 price objective (down from $15.00) on shares of Inozyme Pharma in a research report on Tuesday, November 5th.

Inozyme Pharma Trading Up 2.6 %

INZY opened at $2.72 on Thursday. Inozyme Pharma has a 12 month low of $2.56 and a 12 month high of $7.80. The stock has a market capitalization of $174.73 million, a price-to-earnings ratio of -1.72 and a beta of 1.54. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The business has a fifty day moving average price of $4.53 and a 200 day moving average price of $4.80.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. Sell-side analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Trading of Inozyme Pharma

Large investors have recently made changes to their positions in the company. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma in the 2nd quarter valued at about $76,000. Samlyn Capital LLC boosted its position in shares of Inozyme Pharma by 15.0% in the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after purchasing an additional 437,622 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Inozyme Pharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock valued at $96,000 after purchasing an additional 2,690 shares during the period. Affinity Asset Advisors LLC boosted its position in shares of Inozyme Pharma by 8.1% in the 2nd quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock valued at $12,739,000 after purchasing an additional 213,733 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Inozyme Pharma by 117.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after purchasing an additional 205,417 shares during the period. 88.30% of the stock is owned by institutional investors and hedge funds.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.